论文部分内容阅读
目的研究非小细胞肺癌(NSCLC)组织中S100和S100A4蛋白的表达,探讨S100和S100A4在NSCLC侵袭和转移中的作用。方法应用免疫组化EnVision法检测91例非小细胞肺癌及33例NSCLC癌旁正常肺组织中S100和S100A4蛋白的表达水平。结果NSCLC组织中S100和S100A4的阳性表达率均高于癌旁正常肺组织(P<0.05);S100和S100A4的表达与患者年龄无关(P>0.05);S100的阳性表达与肿瘤大小有关(P<0.05),而S100A4的阳性表达率与肿瘤大小无关(P>0.05);有淋巴结转移者S100的阳性表达率高于无淋巴结转移者(P<0.05);生存时间在1a内患者的S100和S100A4阳性表达率高于存活1a以上者(P<0.05)。在鳞癌患者中,Ⅲ期患者的S100和S100A4的阳性表达率均高于Ⅰ期患者(P<0.05),有淋巴结转移者S100A4的阳性表达率高于无淋巴结转移者(P<0.05);在腺癌患者中,Ⅲ期患者的S100的阳性表达率高于Ⅰ期和Ⅱ期患者(P<0.05)。结论S100和S100A4可能与NSCLC的侵袭、转移和预后相关,可作为评估NSCLC的侵袭、转移和预后的参考指标之一。
Objective To investigate the expression of S100 and S100A4 in non-small cell lung cancer (NSCLC) and to explore the role of S100 and S100A4 in invasion and metastasis of NSCLC. Methods The expression of S100 and S100A4 protein in 91 cases of non-small cell lung cancer and 33 cases of normal lung tissue adjacent to NSCLC were detected by immunohistochemistry EnVision. Results The positive rates of S100 and S100A4 in NSCLC tissues were significantly higher than those in normal lung tissues (P <0.05). The expressions of S100 and S100A4 were not related to the age of patients (P> 0.05). The positive expression of S100 was related to tumor size (P <0.05). The positive expression rate of S100A4 was not related with tumor size (P> 0.05). The positive rate of S100 with lymph node metastasis was higher than that without lymph node metastasis (P <0.05) The positive rate of S100A4 expression was higher than the survival rate of 1a (P <0.05). In squamous cell carcinoma patients, the positive expression rates of S100 and S100A4 in stage Ⅲ patients were higher than those in stage Ⅰ patients (P <0.05). The positive rate of S100A4 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis (P <0.05). In adenocarcinoma patients, the positive expression rate of S100 in stage Ⅲ patients was higher than that in stage Ⅰ and Ⅱ patients (P <0.05). Conclusion S100 and S100A4 may be related to the invasion, metastasis and prognosis of NSCLC, which may be used as a reference index for assessing the invasion, metastasis and prognosis of NSCLC.